600713 南京医药
2025/12 -
人民幣(K¥)

变动
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入54,963,2772.36%53,589,66550,221,56445,123,19539,817,364
减:营业总成本53,921,7232.41%52,645,43949,186,22344,249,16039,093,743
    其中:营业成本51,580,9412.50%50,276,36246,962,43042,185,98537,286,150
               财务费用461,819-10.43%534,751435,170441,844359,591
               资产减值损失(25,113)37.48%(6,248)(6,771)(8,618)(14,994)
公允价值变动收益283----------
投资收益4,79419.30%8,581(48,645)(87,739)(92,916)
    其中:对联营企业和合营企业的投资收益(1,671)-385.44%6,062(519)(2,900)(17,206)
营业利润1,160,10613.36%1,007,443934,323845,713676,261
利润总额1,157,62815.37%978,068906,012838,866677,799
减:所得税费用324,95924.85%265,259190,092228,314207,761
净利润832,66912.05%712,809715,920610,552470,038
减:非控股权益207,83420.49%134,983120,252105,36993,625
股东净利润624,8359.50%577,826595,668505,183376,413

市场价值指针
每股收益 (元) *0.4809.59%0.4450.4750.4850.361
每股派息 (元) *0.1700.00%0.1600.1400.1200.110
每股净资产 (元) *5.4845.15%4.9124.5794.4224.087
审计意见 #标准无保留意见标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容